ARomatherapy for Cognitive Trajectory in Chinese After Coronary Artery Bypass Grafting
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The ARCTIC-CABG (Aromatherapy for Cognitive Trajectory in Chinese after Coronary Artery
Bypass Grafting) trial is a randomized, double-blind, 2-arm, parallel group,
placebo-controlled study to evaluated the effects of Aromatherapy in improving cognitive
function in post-Coronary Artery Bypass Grafting (CABG) patients. The study will recruit 460
patients who undergo a first-time CABG at the Department of Cardiac Surgery in Beijing Anzhen
Hospital.
Baseline information will be collected prior to CABG, all eligible participants undergoing
CABG will be randomly assigned in a 1:1 ratio before hospital discharge to receive
aromatherapy (70% menthol and 30% propanediol) or placebo (10% menthol and 90% propanediol).
The treatment will last for 6 months in both groups. Cognitive function measurement will be
conducted by blinded assessors at baseline (1-3 days before CABG) and at 3- and 6-month after
CABG. The primary outcome will be the change in overall cognitive function (MOCA score) from
baseline to 6-month after CABG.